• Century Therapeutics Inc IPSC.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of five analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -36 cents to -24 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Century Therapeutics Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $19.17 million.

• Century Therapeutics Inc shares had risen by 174.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Century Therapeutics Inc is $4.00, about 31.8% above its last closing price of $2.73

This summary was machine generated from LSEG data March 12 at 02:54 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)